Achieve Life Sciences (ACHV) Net Income towards Common Stockholders (2010 - 2018)
Achieve Life Sciences (ACHV) posted Net Income towards Common Stockholders of -$3.6 million for Q4 2018, down 12.25% on a QoQ basis from -$3.2 million in Q3 2018, and up 2.75% year-over-year from -$3.5 million in Q4 2017.
Achieve Life Sciences (ACHV) Net Income towards Common Stockholders (2010 - 2018) Analysis & Trends
Achieve Life Sciences' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$3.6 million for Q4 2018.
- Quarterly Net Income towards Common Stockholders rose 2.75% year-over-year to -$3.6 million in Q4 2018, while the trailing twelve-month figure through Sep 2019 was -$3.6 million (up 71.56% YoY) and the FY2019 annual result came in at -$16.4 million, down 29.23% from the prior year.
- Net Income towards Common Stockholders was -$3.6 million for Q4 2018 at Achieve Life Sciences, down from -$3.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$166000.0 in Q2 2017 and bottomed at -$9.4 million in Q3 2017.
- A 4-year average of -$2.6 million and a median of -$2.8 million in 2018 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2017 — Net Income towards Common Stockholders plunged 2220.99% — and 2018, when it soared 65.53%.
- Achieve Life Sciences' Net Income towards Common Stockholders stood at -$1.2 million in 2015, then jumped by 50.36% to -$613000.0 in 2016, then slumped by 510.11% to -$3.7 million in 2017, then advanced by 2.75% to -$3.6 million in 2018.
- Business Quant data shows ACHV's Net Income towards Common Stockholders at -$3.6 million in Q4 2018, -$3.2 million in Q3 2018, and -$2.8 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -0.68 |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Achieve Life Sciences | 326.43 Mn | 326.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -3.64 Mn |
| Sep 30, 2018 | -3.24 Mn |
| Jun 30, 2018 | -2.79 Mn |
| Mar 31, 2018 | -3.02 Mn |
| Dec 31, 2017 | -3.74 Mn |
| Sep 30, 2017 | -9.40 Mn |
| Jun 30, 2017 | -166,000.00 |
| Mar 31, 2017 | -329,000.00 |
| Dec 31, 2016 | -613,000.00 |
| Sep 30, 2016 | -405,000.00 |
| Dec 31, 2015 | -1.24 Mn |
| Dec 31, 2012 | -38.09 Mn |
| Sep 30, 2012 | 5.92 Mn |
| Jun 30, 2012 | 4.22 Mn |
| Mar 31, 2012 | -6.86 Mn |
| Dec 31, 2011 | -19.78 Mn |
| Sep 30, 2011 | -4.47 Mn |
| Jun 30, 2011 | 6.53 Mn |
| Mar 31, 2011 | -3.05 Mn |
| Dec 31, 2010 | -2.80 Mn |